SCHEMBL5548405

SCHEMBL5548405

O=CN(Cc1ccccc1)Cc1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
G6PC1 P35575 1/20 0.49
SIGMAR1 Q99720 3/20 0.45
TMEM97 Q5BJF2 2/20 0.45
TAS2R14 Q9NYV8 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CXCR3 P49682 1/20 0.44
NR1D1 P20393 1/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
PKM P14618 1/20 0.41
KDM4E B2RXH2 1/20 0.40
TP53 P04637 1/20 0.40
MEP1A Q16819 1/20 0.40
MEP1B Q16820 1/20 0.40
AGER Q15109 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26802 0.88 ALDH1A1 (0.48) G6PC1MEN1KMT2AMAPTTDP1
SCHEMBL5542363 0.84 TAS2R14 (0.48) G6PC1SIGMAR1TAS2R14KDM4ETP53
SCHEMBL5542200 0.81 KCNA5 (0.50) TAS2R14MEN1KMT2ACNR1CNR2
SCHEMBL5540778 0.81 L3MBTL1 (0.45) SIGMAR1TMEM97MEN1KMT2AL3MBTL1
SCHEMBL5542131 0.80 TAS2R14 (0.45) SIGMAR1TAS2R14MAPTKDM4ENR3C1
SCHEMBL2094150 0.78 CNR2 (0.47) G6PC1SIGMAR1TMEM97MEN1KMT2A
SCHEMBL17333532 0.77 ALDH1A1 (0.40) MEN1KMT2ACNR2TDP1KDM4E
Malonic Acid SCHEMBL16431221 0.77 NPC1 (0.47) MEN1KMT2AL3MBTL1TDP1
SCHEMBL968495 0.76 LMNA (0.48) CNR2KDM4ETP53
SCHEMBL7087904 0.76 TSHR (0.41) MEN1KMT2AL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 G6PC1 2952/4885SIGMAR1 234/4885TMEM97 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.